ReviewHeliyon2024
Cellulose processing using ionic liquids: An analysis of patents and technological trends.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The production of cellulose derivatives using ionic liquid (IL) as solvents and catalysts has become prominent over the last few years, since the process eliminates the use of toxic substances. This study aimed to map and understand the trends in cellulose processing using ILs by a patent analytic approach and technology life cycle modeling. The documents were searched on the Espacenet® and Orbit® platforms.The majority of innovations have come from companies based in developed countries. The data fitted to the sigmoid BiDoseResp model and the life cycle S-curve showed a market in an early stage of maturity. This mapping brings information that subsidizes decision-making regarding investments, research, and innovations aimed at IL-mediated cellulose treatment. Potential markets mostly use ILs of the imidazolium family in polymer chemistry, machinery, and biotechnology technologies. However, medical and pharmaceutical technologies and microstructure and nanostructure applications are still emerging, fostering perspectives for innovation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.